182 related articles for article (PubMed ID: 34862384)
1. Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex.
Pennington LF; Gasser P; Kleinboelting S; Zhang C; Skiniotis G; Eggel A; Jardetzky TS
Nat Commun; 2021 Dec; 12(1):7069. PubMed ID: 34862384
[TBL] [Abstract][Full Text] [Related]
2. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab.
Davies AM; Allan EG; Keeble AH; Delgado J; Cossins BP; Mitropoulou AN; Pang MOY; Ceska T; Beavil AJ; Craggs G; Westwood M; Henry AJ; McDonnell JM; Sutton BJ
J Biol Chem; 2017 Jun; 292(24):9975-9987. PubMed ID: 28438838
[TBL] [Abstract][Full Text] [Related]
3. Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor.
Kim B; Eggel A; Tarchevskaya SS; Vogel M; Prinz H; Jardetzky TS
Nature; 2012 Nov; 491(7425):613-7. PubMed ID: 23103871
[TBL] [Abstract][Full Text] [Related]
4. Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.
Eggel A; Baravalle G; Hobi G; Kim B; Buschor P; Forrer P; Shin JS; Vogel M; Stadler BM; Dahinden CA; Jardetzky TS
J Allergy Clin Immunol; 2014 Jun; 133(6):1709-19.e8. PubMed ID: 24642143
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.
Pennington LF; Tarchevskaya S; Brigger D; Sathiyamoorthy K; Graham MT; Nadeau KC; Eggel A; Jardetzky TS
Nat Commun; 2016 May; 7():11610. PubMed ID: 27194387
[TBL] [Abstract][Full Text] [Related]
6. Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Mitropoulou AN; Ceska T; Heads JT; Beavil AJ; Henry AJ; McDonnell JM; Sutton BJ; Davies AM
Acta Crystallogr F Struct Biol Commun; 2020 Mar; 76(Pt 3):116-129. PubMed ID: 32133997
[TBL] [Abstract][Full Text] [Related]
7. Structural and Physical Basis for Anti-IgE Therapy.
Wright JD; Chu HM; Huang CH; Ma C; Chang TW; Lim C
Sci Rep; 2015 Jun; 5():11581. PubMed ID: 26113483
[TBL] [Abstract][Full Text] [Related]
8. Tracing Human IgE B Cell Antigen Receptor-Bearing Cells With a Monoclonal Anti-Human IgE Antibody That Specifically Recognizes Non-Receptor-Bound IgE.
Zghaebi M; Byazrova M; Flicker S; Villazala-Merino S; Campion NJ; Stanek V; Tu A; Breiteneder H; Filatov A; Khaitov M; Niederberger-Leppin V; Eckl-Dorna J; Valenta R
Front Immunol; 2021; 12():803236. PubMed ID: 34987522
[TBL] [Abstract][Full Text] [Related]
9. The effect of omalizumab treatment on the low affinity immunoglobulin E receptor (CD23/fc epsilon RII) in patients with severe allergic asthma.
Assayag M; Moshel S; Kohan M; Berkman N
Allergy Asthma Proc; 2018 Jan; 39(1):36-42. PubMed ID: 29279058
[TBL] [Abstract][Full Text] [Related]
10. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.
Chu SY; Horton HM; Pong E; Leung IW; Chen H; Nguyen DH; Bautista C; Muchhal US; Bernett MJ; Moore GL; Szymkowski DE; Desjarlais JR
J Allergy Clin Immunol; 2012 Apr; 129(4):1102-15. PubMed ID: 22257644
[TBL] [Abstract][Full Text] [Related]
11. Structure of the omalizumab Fab.
Jensen RK; Plum M; Tjerrild L; Jakob T; Spillner E; Andersen GR
Acta Crystallogr F Struct Biol Commun; 2015 Apr; 71(Pt 4):419-26. PubMed ID: 25849503
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
13. An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases.
Liu P; Pan Z; Gu C; Cao X; Liu X; Zhang J; Xiao Z; Wang X; Guo H; Ju D; Deng SJ
Front Immunol; 2020; 11():596908. PubMed ID: 33329588
[TBL] [Abstract][Full Text] [Related]
14. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors.
Shiung YY; Chiang CY; Chen JB; Wu PC; Hung AF; Lu DC; Pan RL; Chang TW
Immunobiology; 2012 Jul; 217(7):676-83. PubMed ID: 22226669
[TBL] [Abstract][Full Text] [Related]
15. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.
Cohen ES; Dobson CL; Käck H; Wang B; Sims DA; Lloyd CO; England E; Rees DG; Guo H; Karagiannis SN; O'Brien S; Persdotter S; Ekdahl H; Butler R; Keyes F; Oakley S; Carlsson M; Briend E; Wilkinson T; Anderson IK; Monk PD; von Wachenfeldt K; Eriksson PO; Gould HJ; Vaughan TJ; May RD
MAbs; 2014; 6(3):756-64. PubMed ID: 24583620
[TBL] [Abstract][Full Text] [Related]
16. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
Gasser P; Tarchevskaya SS; Guntern P; Brigger D; Ruppli R; Zbären N; Kleinboelting S; Heusser C; Jardetzky TS; Eggel A
Nat Commun; 2020 Jan; 11(1):165. PubMed ID: 31913280
[TBL] [Abstract][Full Text] [Related]
17. Comparable actions of omalizumab on mast cells and basophils.
Serrano-Candelas E; Martinez-Aranguren R; Valero A; Bartra J; Gastaminza G; Goikoetxea MJ; Martín M; Ferrer M
Clin Exp Allergy; 2016 Jan; 46(1):92-102. PubMed ID: 26509363
[TBL] [Abstract][Full Text] [Related]
18. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
[TBL] [Abstract][Full Text] [Related]
19. Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy.
An SB; Yang BG; Jang G; Kim DY; Kim J; Oh SM; Oh N; Lee S; Moon JY; Kim JA; Kim JH; Song YJ; Hyun HW; Kim J; Lee K; Lee D; Kwak MJ; Kim BK; Park YK; Hong CP; Kim JH; Lim HS; Ryu MS; Jin HT; Lee SW; Chang YS; Park HS; Sung YC; Jang MH
Nat Commun; 2022 Sep; 13(1):5669. PubMed ID: 36167830
[TBL] [Abstract][Full Text] [Related]
20. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies.
Mortensen DL; Prabhu S; Stefanich EG; Kadkhodayan-Fischer S; Gelzleichter TR; Baker D; Jiang J; Wallace K; Iyer S; Fielder PJ; Putnam WS
MAbs; 2012; 4(6):724-31. PubMed ID: 23778267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
